S100A4 and breast cancer: In a study of 349 patients with breast cancer, the presence of immunocytochemically-detectable S100A4 in the primary tumours is associated with their early demise when followed up for 19 years (Platt-Higgins et al, 2000; Rudland et al, 2000).